61 related articles for article (PubMed ID: 21386204)
1. Single time point diagnostic breath tests: a review.
Modak AS
J Breath Res; 2010 Mar; 4(1):017002. PubMed ID: 21386204
[TBL] [Abstract][Full Text] [Related]
2. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.
Desta Z; Modak A; Nguyen PD; Lemler SM; Kurogi Y; Li L; Flockhart DA
J Pharmacol Exp Ther; 2009 Apr; 329(1):297-305. PubMed ID: 19136640
[TBL] [Abstract][Full Text] [Related]
3. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need.
Modak AS
J Breath Res; 2017 Dec; 12(1):017101. PubMed ID: 28920579
[TBL] [Abstract][Full Text] [Related]
4. Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited.
Pijls KE; de Vries H; Nikkessen S; Bast A; Wodzig WK; Koek GH
Liver Int; 2014 Apr; 34(4):487-94. PubMed ID: 24428683
[TBL] [Abstract][Full Text] [Related]
5. Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?
Thacker DL; Modak A; Flockhart DA; Desta Z
J Breath Res; 2013 Mar; 7(1):016001. PubMed ID: 23257668
[TBL] [Abstract][Full Text] [Related]
6. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
7. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.
Furuta T; Kodaira C; Nishino M; Yamade M; Sugimoto M; Ikuma M; Hishida A; Watanabe H; Umemura K
Aliment Pharmacol Ther; 2009 Aug; 30(3):294-300. PubMed ID: 19459830
[TBL] [Abstract][Full Text] [Related]
8. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
9. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
10. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Mattison LK; Ezzeldin H; Carpenter M; Modak A; Johnson MR; Diasio RB
Clin Cancer Res; 2004 Apr; 10(8):2652-8. PubMed ID: 15102667
[TBL] [Abstract][Full Text] [Related]
11. Human liver cytochrome P-450 and conjugating enzymes. Hungarian data.
Vereczkey L; Jemnitz K; Monostory K
Acta Physiol Hung; 1997-1998; 85(2):149-52. PubMed ID: 9706309
[TBL] [Abstract][Full Text] [Related]
12. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
13. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
14. (13)C breath tests in personalized medicine: fiction or reality?
Modak AS
Expert Rev Mol Diagn; 2009 Nov; 9(8):805-15. PubMed ID: 19895226
[TBL] [Abstract][Full Text] [Related]
15. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
16. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
18. Breath tests to phenotype drug disposition in oncology.
Opdam FL; Modak AS; Gelderblom H; Guchelaar HJ
Clin Pharmacokinet; 2013 Nov; 52(11):919-26. PubMed ID: 23868281
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
Thacker DL; Modak A; Nguyen PD; Flockhart DA; Desta Z
Chirality; 2011 Nov; 23(10):904-9. PubMed ID: 21935988
[TBL] [Abstract][Full Text] [Related]
20. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
